References
- [1] Aronson, H.. Correction Factor for Dissolution Profile Calculations. J. Pharm. Sc. 1993;82:3549.
- [2] Baratta, J.L., Ngo, A., Lopez, B., Kasabwalla, N., Kenneth, J., Robertson, R.T. Cellular organization of normal mouse liver: A histological, quantitative immunocytochemical, and fine structural analysis. Histochem Cell Bio. 2009;131:713–726.10.1007/s00418-009-0577-1
- [3] Barenholz, Y. Doxil®-The first FDA-approved nano-drug: Lessons learned. J. Control. Release. 2012;160:117–134.10.1016/j.jconrel.2012.03.020
- [4] Barroso, R.P., Basso, L.G.M., Costa-Filho, A.J. Interactions of the antimalarial amodiaquine with lipid model membranes. Chem. Phys. Lipids. 2015;186:68–78.10.1016/j.chemphyslip.2014.12.003
- [5] Basso, L.G.M., Rodrigues, R.Z., Naal, R.M.Z.G., Costa-Filho, A.J. Effects of the antimalarial drug primaquine on the dynamic structure of lipid model membranes. Biochim. Biophys. Acta -Biomembr. 2011;1808:55–64.10.1016/j.bbamem.2010.08.009
- [6] Chen, J., Cheng, D., Li, J., Wang, Y., Guo, J., Chen, Z., Cai, B., Yang, T. Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC. Drug Dev. Ind. Pharm. 2013;39:197–204.
- [7] Chu, C.S., White, N.J. Management of relapsing Plasmodium vivax malaria. Expert Rev. Anti. Infect. Ther. 2016;14:885–900.
- [8] Fasinu, P.S., Tekwani, B.L., Avula, B., Chaurasiya, N.D., Nanayakkara, N.P.D., Wang, Y.-H., Khan, I.A., Walker, L.A. Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine. Malar. J. 2016;15:466.
- [9] Ghosh, A.K., Basu, R., Nandy, P. Lipid perturbation of liposomal membrane of dipalmitoyl phosphatidylcholine by chloroquine sulphate - a fluorescence anisotropic study. Colloids Surfaces B Biointerfaces. 1995;4:1–4.10.1016/0927-7765(94)01155-X
- [10] Gonzalez-Ceron, L., Rodriguez, M.H., Sandoval, M.A., Santillan, F., Galindo-Virgen, S., Betanzos, A.F., Rosales, A.F., Palomeque, O.L. Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. Malar. J. 2015;14:426.
- [11] Jong, E.C., Nothdurft, H.D. Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety. J. Trav. Med. 2001;8:48–56.
- [12] Karyana, M., Devine, A., Kenangalem, E., Burdarm, L., Poespoprodjo, J.R., Vemuri, R., Anstey, N.M., Tjitra, E., Price, R.N., Yeung, S. Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia. Malar. J. 2016;15:536.
- [13] Kedar, P., Warang, P., Sanyal, S., Devendra, R., Ghosh, K., Colah, R. Primaquine-induced severe methemoglobinemia developed during treatment of Plasmodium vivax malarial infection in an Indian family associated with a novel mutation (p.Agr57Trp) in the CYB5R3 gene. Clin. Chim. Acta 2014;437:103–105.
- [14] Kohli, A.G., Kierstead, P.H., Venditto, V.J., Walsh, C.L., Szoka, F.C. Designer lipids for drug delivery: From heads to tails. J. Control. Release. 2014;190:274–287.10.1016/j.jconrel.2014.04.047
- [15] Kokkona, M., Kallinteri, P., Fatouros, D., Antimisiaris, S.G. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition. Eur. J. Pharm. Sci. 2000;9:245–252.
- [16] Kulkarni, S.B., Betageri, G. V, Singh, M. Factors affecting microencapsulation of drugs in liposomes. J. Microencapsul. 1995;12:229–246.10.3109/02652049509010292
- [17] Lasic, D.D., Frederik, P.M., Stuart, M.C., Barenholz, Y., McIntosh, T.J. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett. 1992;312:255–258.10.1016/0014-5793(92)80947-F
- [18] Liang, Y. Drug Release and Pharmacokinetic Properties of Liposomal DB-67 [Theses]. University of Kentucky ;2010.
- [19] Longley, R.J., Sripoorote, P., Chobson, P., Saeseu, T., Sukasem, C., Phuanukoonnon, S., Nguitragool, W., Mueller, I., Sattabongkot, J. High Efficacy of Primaquine Treatment for Plasmodium vivax in Western Thailand. Am. J. Trop. Med. Hyg. 2016;95:1086–1089.
- [20] Marcsisin, S.R., Reichard, G., Pybus, B.S. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art. Pharmacol. Ther. 2016;161:1–10.
- [21] Miatmoko, A., Kawano, K., Yoda, H., Yonemochi, E., Hattori, Y. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent. J. Liposome Res. 2017;27:99–107.10.3109/08982104.2016.116651126982164
- [22] Miatmoko, A., Kawano, K., Yonemochi, E., Hattori, Y. Evaluation of Cisplatin-Loaded Polymeric Micelles and Hybrid Nanoparticles Containing Poly ( Ethylene Oxide ) -Block-Poly ( Methacrylic Acid ) on Tumor Delivery. Pharmacology & Pharmacy. 2016;7:1–8.10.4236/pp.2016.71001
- [23] Mishra, M., Mishra, V.K., Kashaw, V., Iyer, A.K., Kashaw, S.K. Comprehensive review on various strategies for antimalarial drug discovery. Eur. J. Med. Chem. 2017;125:1300–1320.
- [24] Prudêncio, M., Rodriguez, A., Mota, M.M. The silent path to thousands of merozoites: the Plasmodium liver stage. Nat. Rev. Microbiol. 2006;4:849–56.
- [25] Qiu, L., Jing, N., Jin, Y. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method. Int. J. Pharm. 2008;361:56–63.
- [26] Recht, J., White, N.J., Ashley, E., Safety of 8-Aminoquinoline Antimalarial Medicines. Geneva: World Health Organization, 2015.
- [27] Stela Santos-Magalhães, N., Carla Furtado Mosqueira, V. Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev. 2009;62:560–575.
- [28] Stensrud, G., Sande, S.A., Kristensen, S., Smistad, G. Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int. J. Pharm. 2000;198:213–228.
- [29] World Health Organization. Guidelines for the treatment of malaria, Third Edit. ed. Geneva: World Health Organization, 2015.
- [30] Yadav, A. V., Murthy, M.S., Shete, A.S., Sakhare, S. Stability aspects of liposomes. Indian J. Pharm. Educ. Res. 2011;45:402–413.